Dolphin
Senior Member (Voting Rights)
https://openresearch.nihr.ac.uk/articles/5-39/v1
Research Article
Defining a High-Quality Myalgic Encephalomyelitis/Chronic Fatigue Syndrome cohort in UK Biobank
[version 1; peer review: awaiting peer review]
Gemma L. Samms1, Chris P. Ponting
Abstract
Background
Progress in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) research is being slowed by the relatively small-scale studies being performed whose results are often not replicated. Progress could be accelerated by analyses of large population-scale projects, such as UK Biobank (UKB), which provide extensive phenotype and genotype data linked to both ME/CFS cases and controls.
Methods
Here, we analysed the overlap and discordance among four UKB-defined ME/CFS cohorts, and additional questionnaire data when available.
Results
A total of 5,354 UKB individuals were linked to at least one piece of evidence of MECFS, a higher proportion (1.1%) than most prevalence estimates. Only a third (36%; n=1,922) had 2 or more pieces of evidence for MECFS, in part due to data missingness. For the same UKB participant, ME/CFS status defined by ICD-10 (International Classification of Diseases, Tenth Revision) code G93.3 (Post-viral fatigue syndrome) was most likely to be supported by another data type (72%); ME/CFS status defined by Pain Questionnaire responses is least likely to be supported (43%), in part due to data missingness.
Conclusions
We conclude that ME/CFS status in UKB, and potentially other biobanks, is best supported by multiple, and not single, lines of evidence. Finally, we raise the estimated ME/CFS prevalence in the UK to 410,000 using the most consistent evidence for ME/CFS status, and accounting for those who had no opportunity to participate in UKB due to being bed- or house-bound.
Plain Language Summary
Plain English summary
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) is a highly debilitating and relatively common disease whose causes are unknown. Most of its research compares features (symptoms, molecules, cells or genes, for example) from small numbers of people with ME/CFS, against these features from others without the disease. Studies using small sample sizes have not yielded replicated discoveries that would quicken the pace of ME/CFS research towards effective therapies.
Alternatively, ME/CFS research could take advantage of population-scale bioresources, such as the UK Biobank, which holds diverse genetic, molecular, cellular, imaging and questionnaire data on nearly 500,000 individuals. This has the added advantage of being cheaper than recruiting a new cohort, and generating new data.
For ME/CFS, this approach raises the difficulty of how to best categorise people with this disease, for example by questionnaire response or through linked electronic health records. In the UK Biobank, there are four ways to categorise people with ME/CFS.
This study’s results show that just over 1% of the UK Biobank participants could be categorised as having a ME/CFS medical diagnosis. However, not all evidence for their ME/CFS diagnosis is consistent.
By cross-referencing different data in UK Biobank, we show that a participant’s ME/CFS diagnosis is best supported by two or more lines of evidence. Using the most consistent evidence, and accounting for those who – due to their illness – could not participate in the UK Biobank, we estimate that the UK’s prevalence of ME/CFS is 410,000.
Keywords
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome prevalence; Population bioresource; Electronic health records; Post-viral fatigue syndrome
https://bsky.app/profile/cgatist.bsky.social/post/3lnuillx7us26
Research Article
Defining a High-Quality Myalgic Encephalomyelitis/Chronic Fatigue Syndrome cohort in UK Biobank
[version 1; peer review: awaiting peer review]
Gemma L. Samms1, Chris P. Ponting
Abstract
Background
Progress in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) research is being slowed by the relatively small-scale studies being performed whose results are often not replicated. Progress could be accelerated by analyses of large population-scale projects, such as UK Biobank (UKB), which provide extensive phenotype and genotype data linked to both ME/CFS cases and controls.
Methods
Here, we analysed the overlap and discordance among four UKB-defined ME/CFS cohorts, and additional questionnaire data when available.
Results
A total of 5,354 UKB individuals were linked to at least one piece of evidence of MECFS, a higher proportion (1.1%) than most prevalence estimates. Only a third (36%; n=1,922) had 2 or more pieces of evidence for MECFS, in part due to data missingness. For the same UKB participant, ME/CFS status defined by ICD-10 (International Classification of Diseases, Tenth Revision) code G93.3 (Post-viral fatigue syndrome) was most likely to be supported by another data type (72%); ME/CFS status defined by Pain Questionnaire responses is least likely to be supported (43%), in part due to data missingness.
Conclusions
We conclude that ME/CFS status in UKB, and potentially other biobanks, is best supported by multiple, and not single, lines of evidence. Finally, we raise the estimated ME/CFS prevalence in the UK to 410,000 using the most consistent evidence for ME/CFS status, and accounting for those who had no opportunity to participate in UKB due to being bed- or house-bound.
Plain Language Summary
Plain English summary
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) is a highly debilitating and relatively common disease whose causes are unknown. Most of its research compares features (symptoms, molecules, cells or genes, for example) from small numbers of people with ME/CFS, against these features from others without the disease. Studies using small sample sizes have not yielded replicated discoveries that would quicken the pace of ME/CFS research towards effective therapies.
Alternatively, ME/CFS research could take advantage of population-scale bioresources, such as the UK Biobank, which holds diverse genetic, molecular, cellular, imaging and questionnaire data on nearly 500,000 individuals. This has the added advantage of being cheaper than recruiting a new cohort, and generating new data.
For ME/CFS, this approach raises the difficulty of how to best categorise people with this disease, for example by questionnaire response or through linked electronic health records. In the UK Biobank, there are four ways to categorise people with ME/CFS.
This study’s results show that just over 1% of the UK Biobank participants could be categorised as having a ME/CFS medical diagnosis. However, not all evidence for their ME/CFS diagnosis is consistent.
By cross-referencing different data in UK Biobank, we show that a participant’s ME/CFS diagnosis is best supported by two or more lines of evidence. Using the most consistent evidence, and accounting for those who – due to their illness – could not participate in the UK Biobank, we estimate that the UK’s prevalence of ME/CFS is 410,000.
Keywords
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome prevalence; Population bioresource; Electronic health records; Post-viral fatigue syndrome
https://bsky.app/profile/cgatist.bsky.social/post/3lnuillx7us26